Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-08
2010-06-15
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S320100, C435S455000, C536S023100, C536S024300, C536S024500
Reexamination Certificate
active
07737124
ABSTRACT:
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG.1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
REFERENCES:
patent: 5258289 (1993-11-01), Davis et al.
patent: 5650309 (1997-07-01), Wong-Stall et al.
patent: 5859310 (1999-01-01), Bujard et al.
patent: 5883081 (1999-03-01), Kraus et al.
patent: 6022962 (2000-02-01), Chowrira et al.
patent: 6060317 (2000-05-01), Malech
patent: 6074836 (2000-06-01), Bordignon et al.
patent: 6096538 (2000-08-01), Kingsman et al.
patent: 6100087 (2000-08-01), Rossi et al.
patent: 6218186 (2001-04-01), Choi et al.
patent: 6255071 (2001-07-01), Beach et al.
patent: 6274788 (2001-08-01), Kumar et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6635472 (2003-10-01), Lauermann
patent: 2003/0084471 (2003-05-01), Beach et al.
patent: 2003/0124513 (2003-07-01), McSwiggen
patent: 2003/0143204 (2003-07-01), Lewis et al.
patent: 2003/0219823 (2003-11-01), Alsobrook et al.
patent: 2004/0072771 (2004-04-01), Symonds et al.
patent: 2005/0221354 (2005-10-01), Mounts
“Mutant Gene Produces Strong Natural Resistance to HIV-1 Infection in 1 in 100 People”, University of Pennsylvania Health System, News and Periodicals, Aug. 8, 1996, pp. 1-3.
“Pushing the Envelope” Howard Hughes Medical Institute (HHMI) News, Nov. 21, 1997, pp. 1-2.
“Scientists suggest new approaches for development of AIDS drugs and vaccines” National Cancer Institute, Charity Wire, Article 01853, Jun. 21, 1999, pp. 1-3.
An et al., Mol. Ther. 14, 494-504 (2006).
Arendt et al. “Vector Systems for the Delivery of Small Interfering RNAs: Managing the RISC**” ChemBioChem 2003, 4, pp. 1129-1136.
Baltimore, Nature 335, 395-396 (1988).
Banerjea Akhil et al., “Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages”, Molecular Therapy : The Journal of American Society of Gene Therapy, Jul. 2003, pp. 62-71, vol. 8, No. 1.
Barton G M et al., “Retroviral delivery of small interfering RNA into primary cells”, PNAS, Nov. 12, 2002, pp. 14943-14945, vol. 99, No. 23, Washington, USA.
Brummelkamp et al., “A system for stable expression of short interfering RNAs in mammalian cells.” Apr. 19, 2002, vol. 296, pp. 550-553.
Caplen et al., Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems, PNAS, p. 9742-9747, Aug. 14, 2001, vol. 98.
Chatterjee et al. “Dual-target inhibition of HIV-1 in virto by means of an adeno-associated antisense vector.” Science, Nov. 27, 1992, vol. 258, pp. 1485-1488.
Consiglio et al., “In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice”, Nature Medicine, Mar. 2001, pp. 310-316, vol. 7, No. 3.
Czauderna Frank et al., “Inducible shRNA expression for application in a prostate cancer mouse model”, Nucleic Acids Research, Nov. 1, 2003, p. e127, vol. 31, No. 21.
David Lawrence, RNAi could hold promise in the treatment of HIV, The Lancet, p. 207, Jun. 8, 2002, vol. 359.
De Palma et al., “In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors”, Human Gene Therapy, Aug. 10, 2003, pp. 1193-1206, vol. 14.
Devroe E. & Silver P A, “Retrovirus-delivered siRNA”, BMC Technology, Aug. 28, 2002, pp. 1-5.
Fire et al., Nature 391, 806 (1998).
Fish and Kruithof, BMC.Mol.Biol. 5, 9 (2004).
Gatlin et al. Jun. 2001. Long-term engraftment of nonobese diabetic/severe combined immunodeficient mice with human CD34+ cells transduced by a self-inactivating human immunodeficiency virus type I vector. Human Gene Therapy. vol. 12. 1079-1089.
Godwin et al. Oct. 1998. Detection of targeted GFP-Hox gene fusions during mouse embryogenisis. PNAS. vol. 95. 13042-10347.
Grimm et al., Nature. 441, 537-541 (2006).
Ilves et al. 1996. Retroviral Vectors designed for targeted expression of RNA polymerases III-driven transcripts: a comparative study. Gene. vol. 171. 203-208.
International Search Report for PCT/US08/56245, Sep. 3, 2008.
Iwakuma et al. 1999. Self-inactivating Lentiviral Vectors with U3 and U5 Modifications. Virology. vol. 261, 120-132.
Jackson et al., RNA. 12, 1179-1187 (2006).
Jacque et al., Modulation of HIV-1 replication by RNA interference, Nature, p. 435-438, Jul. 25, 2002, vol. 418.
Junker et al. 1994. Reduction in replication of the human immunodeficiency virus type I in human T cell lines by polymerase III-driven transcription of chemeric tRNA-antisense RNA genes. Antisense Research and Development. vol. 4. 165-172.
Kafri et al. Jun. 2000. Lentiviral Vectgors: Regulated gene expression. Molecular Therapy. vol. 1., No. 6. 516-521.
Lee N S et al., “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells”, Nature Biotechnology, May 2002, pp. 500-505, vol. 19.
Li et al., “Inhibition of HIV-1 infection by lentiviral vectors expressing pol III-promoted anti-HIV RNAs”, Molecular Therapy, Academic Press, Aug. 2003, pp. 196-206, vol. 8, No. 2, San Diego, CA, USA.
Lieberman et al., “Interfering with disease: opportunities and roadblocks to harnessing RNA interference,” Trends in Molecular Medicine, vol. 9, No. 9 Sep. 2003, pp. 397-403.
Lois Carlos et al., “Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors”, Science, Feb. 1, 2002, pp. 868-872, vol. 295, No. 5556.
Martinez, L.J., “Katy, bar the door! HIV entry inhibitors”, Research Initiative/Treatment Action Article, Jun. 2000, pp. 1-2.
Matsukura S et al., “Establishment of conditional vectors for hairpin siRNA knockdowns”, Nucleic Acids Research, Aug. 1, 2003, pp. e77 (1-5), vol. 31, No. 15, Oxford University.
Miyagishi M. et al., “U6 promoter-driven sirnas with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells”, Nature Biotechnology, May 2002, pp. 497-500, vol. 19, No. 5, US.
Miyoshi et al., “Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector”, Medical Sciences, Sep. 1997, pp. 10319-10323, vol. 94.
Miyoshi H. et al. “Development of a self-inactivating lentivirus vector”, Journal of Virology, 1998, pp. 8150-8157, vol. 72, No. 10.
Mummidi et al., “The human CC chemokine Receptor 5 (CCR5) gene” Jour. Biol. Chem., Dec. 5, 1997, vol. 272, p. 30662, col. 2, lines 11-13.
Naldini L. et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector” Science, Apr. 12, 1996, vol. 272.
Novina et al., siRNA-directed inhibition of HIV-1 infection, Nature Medicine, p. 681-686, Jul. 2002, vol. 8.
Ogueta et al. 2001. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Molecular Medicine. Vo.. 7, No. 8. 569-579.
Ohkawa J. et al., “Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter”, Human Gene Therapy, Mar. 1, 2000, pp. 577-585, vol. 11, No. 4.
Paddison et al., Short hairpin RNAs (
An Dong Sung
Baltimore David
Chen Irvin S. Y.
Lois-Caballe Carlos
Qin Xiao-Feng
California Institute of Technology
Knobbe Martens Olson & Bear LLP
The Regents of the University of California
Zara Jane
LandOfFree
Method for expression of small antiviral RNA molecules with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for expression of small antiviral RNA molecules with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for expression of small antiviral RNA molecules with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220126